Lateral neck dissection for aggressive variants of well-differentiated thyroid cancer

Davide Lombardi, Stefano Taboni, Alberto Paderno, Davide Giordano, Francesco Bertagna, Domenico Albano, Verter Barbieri, Giuseppe Spriano, Giuseppe Mercante, Simonetta Piana, Salvatore Bellafiore, Carlo Cappelli, Piero Nicolai

Research output: Contribution to journalArticle

Abstract

Objective: Well-differentiated thyroid cancer (WDTC) is characterized by favorable disease course and excellent survival. However, some histologic subtypes, known as aggressive histologic variants (AHVs), present a more aggressive behavior than conventional WDTC. The aim of this study was to evaluate the pattern of nodal involvement and factors influencing prognosis in N1b patients with AHVs. Methods: A multicentric retrospective analysis of patients who underwent therapeutic lateral neck dissection (ND) for WDTC between 1994 and 2015 was accomplished. AHVs included the following subtypes: Tall cell, Hürtle cell, diffuse sclerosing, and poorly differentiated papillary thyroid cancer. Results: The study included a total of 352 N1b patients, 40 (11.4%) of whom had AHVs. AHVs present a similar distribution of positive nodes if compared with conventional WDTC. In AHV patients, 5-year overall survival (OS), disease-specific survival (DSS), locoregional control, and metastasis-free survival were 82.2%, 93.6%, 80.3%, and 87.3%, respectively. Advanced age (>55 years) was the only significant factor affecting survival (OS, P<.001; DSS, P = .011) in this group. In the AHV group, there were 9 (22.5%) recurrences; patients with regional recurrence and without distant metastases were effectively treated by surgery. Conclusion: The distribution of positive lymph nodes in case of AHVs is similar to that of conventional WDTC, with only level V at a relatively greater risk of harboring metastases in the former group. Survival outcomes in N1b patients with AHVs remain optimal. Total thyroidectomy, ND, and adjuvant radioiodine administration have been demonstrated to be effective treatments in the setting of AHVs.

Original languageEnglish
Pages (from-to)328-334
Number of pages7
JournalEndocrine Practice
Volume25
Issue number4
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Neck Dissection
Thyroid Neoplasms
Survival
Neoplasm Metastasis
Recurrence
Thyroidectomy
Lymph Nodes
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Lombardi, D., Taboni, S., Paderno, A., Giordano, D., Bertagna, F., Albano, D., ... Nicolai, P. (2019). Lateral neck dissection for aggressive variants of well-differentiated thyroid cancer. Endocrine Practice, 25(4), 328-334. https://doi.org/10.4158/EP-2018-0503

Lateral neck dissection for aggressive variants of well-differentiated thyroid cancer. / Lombardi, Davide; Taboni, Stefano; Paderno, Alberto; Giordano, Davide; Bertagna, Francesco; Albano, Domenico; Barbieri, Verter; Spriano, Giuseppe; Mercante, Giuseppe; Piana, Simonetta; Bellafiore, Salvatore; Cappelli, Carlo; Nicolai, Piero.

In: Endocrine Practice, Vol. 25, No. 4, 01.04.2019, p. 328-334.

Research output: Contribution to journalArticle

Lombardi, D, Taboni, S, Paderno, A, Giordano, D, Bertagna, F, Albano, D, Barbieri, V, Spriano, G, Mercante, G, Piana, S, Bellafiore, S, Cappelli, C & Nicolai, P 2019, 'Lateral neck dissection for aggressive variants of well-differentiated thyroid cancer', Endocrine Practice, vol. 25, no. 4, pp. 328-334. https://doi.org/10.4158/EP-2018-0503
Lombardi, Davide ; Taboni, Stefano ; Paderno, Alberto ; Giordano, Davide ; Bertagna, Francesco ; Albano, Domenico ; Barbieri, Verter ; Spriano, Giuseppe ; Mercante, Giuseppe ; Piana, Simonetta ; Bellafiore, Salvatore ; Cappelli, Carlo ; Nicolai, Piero. / Lateral neck dissection for aggressive variants of well-differentiated thyroid cancer. In: Endocrine Practice. 2019 ; Vol. 25, No. 4. pp. 328-334.
@article{310cdf4cc4244ff4a8fa0c2af102e1d8,
title = "Lateral neck dissection for aggressive variants of well-differentiated thyroid cancer",
abstract = "Objective: Well-differentiated thyroid cancer (WDTC) is characterized by favorable disease course and excellent survival. However, some histologic subtypes, known as aggressive histologic variants (AHVs), present a more aggressive behavior than conventional WDTC. The aim of this study was to evaluate the pattern of nodal involvement and factors influencing prognosis in N1b patients with AHVs. Methods: A multicentric retrospective analysis of patients who underwent therapeutic lateral neck dissection (ND) for WDTC between 1994 and 2015 was accomplished. AHVs included the following subtypes: Tall cell, H{\"u}rtle cell, diffuse sclerosing, and poorly differentiated papillary thyroid cancer. Results: The study included a total of 352 N1b patients, 40 (11.4{\%}) of whom had AHVs. AHVs present a similar distribution of positive nodes if compared with conventional WDTC. In AHV patients, 5-year overall survival (OS), disease-specific survival (DSS), locoregional control, and metastasis-free survival were 82.2{\%}, 93.6{\%}, 80.3{\%}, and 87.3{\%}, respectively. Advanced age (>55 years) was the only significant factor affecting survival (OS, P<.001; DSS, P = .011) in this group. In the AHV group, there were 9 (22.5{\%}) recurrences; patients with regional recurrence and without distant metastases were effectively treated by surgery. Conclusion: The distribution of positive lymph nodes in case of AHVs is similar to that of conventional WDTC, with only level V at a relatively greater risk of harboring metastases in the former group. Survival outcomes in N1b patients with AHVs remain optimal. Total thyroidectomy, ND, and adjuvant radioiodine administration have been demonstrated to be effective treatments in the setting of AHVs.",
author = "Davide Lombardi and Stefano Taboni and Alberto Paderno and Davide Giordano and Francesco Bertagna and Domenico Albano and Verter Barbieri and Giuseppe Spriano and Giuseppe Mercante and Simonetta Piana and Salvatore Bellafiore and Carlo Cappelli and Piero Nicolai",
year = "2019",
month = "4",
day = "1",
doi = "10.4158/EP-2018-0503",
language = "English",
volume = "25",
pages = "328--334",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "4",

}

TY - JOUR

T1 - Lateral neck dissection for aggressive variants of well-differentiated thyroid cancer

AU - Lombardi, Davide

AU - Taboni, Stefano

AU - Paderno, Alberto

AU - Giordano, Davide

AU - Bertagna, Francesco

AU - Albano, Domenico

AU - Barbieri, Verter

AU - Spriano, Giuseppe

AU - Mercante, Giuseppe

AU - Piana, Simonetta

AU - Bellafiore, Salvatore

AU - Cappelli, Carlo

AU - Nicolai, Piero

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Objective: Well-differentiated thyroid cancer (WDTC) is characterized by favorable disease course and excellent survival. However, some histologic subtypes, known as aggressive histologic variants (AHVs), present a more aggressive behavior than conventional WDTC. The aim of this study was to evaluate the pattern of nodal involvement and factors influencing prognosis in N1b patients with AHVs. Methods: A multicentric retrospective analysis of patients who underwent therapeutic lateral neck dissection (ND) for WDTC between 1994 and 2015 was accomplished. AHVs included the following subtypes: Tall cell, Hürtle cell, diffuse sclerosing, and poorly differentiated papillary thyroid cancer. Results: The study included a total of 352 N1b patients, 40 (11.4%) of whom had AHVs. AHVs present a similar distribution of positive nodes if compared with conventional WDTC. In AHV patients, 5-year overall survival (OS), disease-specific survival (DSS), locoregional control, and metastasis-free survival were 82.2%, 93.6%, 80.3%, and 87.3%, respectively. Advanced age (>55 years) was the only significant factor affecting survival (OS, P<.001; DSS, P = .011) in this group. In the AHV group, there were 9 (22.5%) recurrences; patients with regional recurrence and without distant metastases were effectively treated by surgery. Conclusion: The distribution of positive lymph nodes in case of AHVs is similar to that of conventional WDTC, with only level V at a relatively greater risk of harboring metastases in the former group. Survival outcomes in N1b patients with AHVs remain optimal. Total thyroidectomy, ND, and adjuvant radioiodine administration have been demonstrated to be effective treatments in the setting of AHVs.

AB - Objective: Well-differentiated thyroid cancer (WDTC) is characterized by favorable disease course and excellent survival. However, some histologic subtypes, known as aggressive histologic variants (AHVs), present a more aggressive behavior than conventional WDTC. The aim of this study was to evaluate the pattern of nodal involvement and factors influencing prognosis in N1b patients with AHVs. Methods: A multicentric retrospective analysis of patients who underwent therapeutic lateral neck dissection (ND) for WDTC between 1994 and 2015 was accomplished. AHVs included the following subtypes: Tall cell, Hürtle cell, diffuse sclerosing, and poorly differentiated papillary thyroid cancer. Results: The study included a total of 352 N1b patients, 40 (11.4%) of whom had AHVs. AHVs present a similar distribution of positive nodes if compared with conventional WDTC. In AHV patients, 5-year overall survival (OS), disease-specific survival (DSS), locoregional control, and metastasis-free survival were 82.2%, 93.6%, 80.3%, and 87.3%, respectively. Advanced age (>55 years) was the only significant factor affecting survival (OS, P<.001; DSS, P = .011) in this group. In the AHV group, there were 9 (22.5%) recurrences; patients with regional recurrence and without distant metastases were effectively treated by surgery. Conclusion: The distribution of positive lymph nodes in case of AHVs is similar to that of conventional WDTC, with only level V at a relatively greater risk of harboring metastases in the former group. Survival outcomes in N1b patients with AHVs remain optimal. Total thyroidectomy, ND, and adjuvant radioiodine administration have been demonstrated to be effective treatments in the setting of AHVs.

UR - http://www.scopus.com/inward/record.url?scp=85064731046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064731046&partnerID=8YFLogxK

U2 - 10.4158/EP-2018-0503

DO - 10.4158/EP-2018-0503

M3 - Article

C2 - 30995431

AN - SCOPUS:85064731046

VL - 25

SP - 328

EP - 334

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 4

ER -